SIBN

Analyst Note: SI-BONE, Inc. (SIBN)

Date: 2026-06-20 Current Price: $15.84

1. Structural Readiness

• Conservative Entry: Not yet triggered (requires confirmed breakout above the coil resistance).
• Aggressive/Pre-Breakout Entry: Not recommended for conservative sizing; the setup is currently in the "forming" phase.
• Breakout Level: The resistance level defining the breakout is not explicitly quantified in the text, but it sits above the current price of $15.84.
• Extension: Not applicable (price is within the forming range, not extended above the breakout).
• ATR Context: Current ATR is 4.3% (High). This indicates elevated volatility, which is consistent with a forming setup in a small-cap healthcare name. The ATR-at-breakout is not yet determined as the breakout has not fired.

2. Thesis Layer

• Thesis Classification: Tactical, Setup-Led.
• Macro Thesis: There is no named secular thesis attached to this specific setup at this date. The investment case is not driven by a broad macro narrative but by the specific quality of the technical setup combined with the company's fundamental execution.
• Judgment Criteria: The conviction must be derived strictly from the setup quality (the forming coil structure) and the business fundamentals (revenue guidance, margin expansion, and reimbursement tailwinds) as reported by management. No external macro assumptions should be invented to support the thesis.

3. Business Overview

• Company Description: SI-BONE, Inc. is a leader in developing and commercializing differentiated solutions for surgical and interventional procedures for patients with compromised bone. The company focuses on the sacroiliac (SI) joint and spinal pelvic fusion markets.
• Business Model: The company utilizes a hybrid sales model consisting of a direct sales force (territory sales managers and clinical support specialists) and third-party sales agents in the U.S. and internationally.
• Key Fundamentals (as of May 11, 2026):
• Revenue Guidance: Management increased full-year revenue guidance to a range of $230 million to $233 million.
• Margin Expansion: Annual gross margin expectations were raised to approximately 79%, an increase of 100 basis points from prior guidance.
• Product Pipeline: A third breakthrough device is advancing on schedule, with verification and validation nearing completion. Management targets a 510(k) submission in the early third quarter of 2026.
• Reimbursement Tailwinds:
• NTAP: On October 1, 2025, CMS awarded the iFuse TORQ TNT implant a New Technology Add-on Payment (NTAP), providing incremental reimbursement up to $4,136 per procedure (expiring Sept 30, 2028).
• TPT: Effective Jan 1, 2025, hospital outpatient departments and ASCs are eligible for Transitional Pass-Through (TPT) payment for iFuse Bedrock Granite.
• DRG Impact: Management notes that the increase in average hospital payment under proposed new DRGs could be as high as $50,000 per procedure depending on diagnosis and severity.
• Commercial Scale: As of March 31, 2026, nearly 150,000 procedures have been performed using their technologies since commercialization. The U.S. commercial organization includes 89 territory sales managers and 336 third-party sales agents.
• Efficiency: Trailing twelve-month average revenue per territory sales manager increased to $2.2 million (from $2.0 million in 2025).
• Liquidity: Management states that existing cash and marketable securities will fund operating expenses and capital expenditure requirements for the next 12 months.

4. Archetype and Conviction

• Archetype: Deep Value Recovery (with strong Growth characteristics).
• *Fit:* The company is demonstrating a clear inflection point in profitability (margin expansion to 79%) and revenue acceleration (guidance raise), supported by a large, under-penetrated market (30 million adults with chronic lower back pain, 15-30% SI joint origin). The "Deep Value" aspect is reflected in the improving unit economics and the "Recovery" in the form of scaling from a base of 150k procedures to a target of 300k annual procedures.
• Conviction Stack:
• Thesis Strength: Moderate. The thesis is tactical and setup-led, lacking a broad macro anchor, but the business fundamentals are robust.
• Evidence Quality: High. Multiple primary sources (earnings transcripts, 10-Q/10-K filings) confirm revenue growth, margin expansion, and reimbursement tailwinds.
• Structural Quality: Positive. The forming coil indicates a healthy consolidation phase after a catalyst. The ATR of 4.3% (High) suggests active interest but requires careful position sizing.
• Setup Readiness: Partial. The coil is forming, not confirmed. This is a positive signal but not a trigger for a full conservative entry.
• Rerating Potential: Significant. The combination of margin expansion, new product submissions (Q3 2026), and reimbursement upgrades (NTAP/TPT) provides a clear path for multiple expansion if the breakout occurs.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen: A confirmed breakout above the coil resistance level, accompanied by volume expansion. Continued execution on the Q3 510(k) submission would also reinforce the growth narrative.
• Gaps in Evidence:
• Breakout Level: The specific resistance price required for a confirmed breakout is not quantified.
• Cash Runway Details: While management states cash is sufficient for 12 months, the exact cash balance and burn rate are not detailed in the provided evidence snippets.
• Competitive Landscape: No specific data on competitor pricing or market share shifts is provided in the evidence block.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management raised full-year revenue guidance to $230-$233 million and gross margins to 79%; NTAP and TPT reimbursement tailwinds provide significant pricing power; 150,000 cumulative procedures and expanding sales force indicate strong commercial traction. Key risks: Setup is currently "forming" and not yet confirmed; high ATR (4.3%) indicates elevated volatility and potential for sharp drawdowns if structure breaks; reliance on third-party sales agents introduces execution risk; reimbursement changes remain subject to CMS finalization. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" status and high volatility; treat as a partial allocation pending confirmation. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).